Deals
Pacira Holders Get $36.50 A Share As Viatris Completes Its Cash Purchase
About 66% of Pacira shares were tendered, and the non-opioid pain-treatment company became a wholly owned Viatris subsidiary.
Pacira BioSciences (PCRX) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Deals
About 66% of Pacira shares were tendered, and the non-opioid pain-treatment company became a wholly owned Viatris subsidiary.
Deals
Pacira and its board plan to defend their merger disclosures, while shareholders have sent 15 demand letters.
SEC Filings
The dispute concerns its biggest product and a judgment that brought Pacira $28.3 million in repayment and interest.
Deals
Pacira will issue no third-quarter results and no outlook updates while Viatris' $36.50-a-share cash tender offer is pending.
Deals
Goldman Sachs called the price fair, and four of five other potential buyers passed, the board says.
Deals
The offer has no financing condition and follows an October 8 merger agreement, with Pacira shares closing Thursday at $36.39.
SEC Filings
An amendment to Doma's Schedule 13D says the group fell below 5% of Pacira on October 8, with sales at $36.29 and $36.34 a share.
Deals
The tender offer for the maker of Exparel and Zilretta must launch within 15 business days, with a close targeted by the end of 2026.